Compare PVL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PVL | SCYX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 51.4M |
| IPO Year | N/A | 2014 |
| Metric | PVL | SCYX |
|---|---|---|
| Price | $1.84 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 60.4K | ★ 83.3K |
| Earning Date | 03-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.43% | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $0.57 |
| 52 Week High | $2.04 | $6.09 |
| Indicator | PVL | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 57.53 |
| Support Level | $1.73 | $4.65 |
| Resistance Level | $1.92 | $5.56 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 64.36 | 34.87 |
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.